Hainan CITIC Bio-Pharmaceutical Development

Hainan CITIC Bio-Pharmaceutical Development is a Chinese biotechnology company specializing in the development and commercialization of innovative biological therapies, particularly in the field of oncology. As a subsidiary within the CITIC Group's healthcare division, the company is a key player in the production and distribution of Oncorine (H101), the world's first approved oncolytic virus therapy for nasopharyngeal carcinoma. The company operates advanced manufacturing facilities in Haikou, Hainan, which are equipped for large-scale production of recombinant proteins and viral vectors. Its research focus extends to genetic engineering and the development of treatments for various solid tumors. Hainan CITIC Bio-Pharmaceutical Development plays a strategic role in advancing China's domestic biopharmaceutical capabilities through its specialized technology platforms.